Moderna, Inc. (NASDAQ: MRNA)

Sector: Healthcare Industry: Biotechnology CIK: 0001682852
Market Cap 18.75 Bn
P/E -6.63
P/S 9.65
Div. Yield 0.00
ROIC (Qtr) -0.35
Total Debt (Qtr) 590.00 Mn
Revenue Growth (1y) (Qtr) -29.81
Add ratio to table...

About

Moderna, Inc., often recognized by its stock symbol MRNA, is a biotechnology company operating within the pharmaceutical industry. Its primary business activities revolve around the development of messenger RNA (mRNA) medicines for various diseases and conditions, including infectious diseases, cancer, and rare genetic disorders. Moderna's mRNA platform aims to facilitate rapid development and manufacturing of mRNA-based medicines, catering to a wide range of medical needs. The company's revenue is mainly generated through its primary products...

Read more

Investment thesis

Bull case

  • Moderna’s 2025 financial performance demonstrates a disciplined execution that has translated into a 30% reduction in operating expenses and a 31% cut in R&D spend, while still maintaining a robust cash balance of $8.1 billion. The company’s ability to lower cost of sales by 41%—driven by higher productivity, reduced inventory write‑downs and the wind‑down of contract‑manufacturing costs—shows that the cost‑discipline program is delivering real, tangible results that free cash for future investment. Importantly, the company’s cash draw from the credit facility was only $600 million, a modest fraction of the $1.5 billion line, and the company achieved $1.8 billion in cash improvement over 2025 guidance. This financial leeway positions Moderna to sustain its R&D pipeline while expanding commercialization in key markets.
  • International growth is a cornerstone of Moderna’s 2026 outlook, with the company projecting a 10% revenue increase that is largely driven by new and expanded operations outside the United States. The company has secured multi‑year agreements with the United Kingdom, Canada, Australia, Mexico, Taiwan, and Brazil that provide access to local manufacturing, regulatory support, and distribution channels. These agreements are strategically designed to capture market share in countries where vaccination demand is rising, especially for COVID and respiratory vaccines, and the company’s own launch of MNEXT Spike in the U.S. has already secured 24% of the U.S. retail market, with a 34% share among seniors. A second year of MNEXT Spike sales is expected to build on this momentum, and the company is poised to replicate this success in Europe, Japan, and Taiwan.
  • Moderna’s vaccine portfolio is expanding beyond COVID‑19 to address a range of respiratory diseases, creating multiple revenue streams. The company’s RSV vaccine, Emresvia, has received approvals in 40 countries and targets both high‑risk and older adults, while the seasonal flu vaccine, mRNA‑1010, is currently under review in Europe, Canada, and Australia. Even though the U.S. FDA has deferred review of the flu program, Moderna has a clear path forward internationally and is actively preparing for a 2027 launch in the U.S. once regulatory clarity is achieved. In addition, a flu‑COVID combination vaccine is progressing through European and Canadian reviews, with a potential launch in 2026 that could generate significant incremental revenue. These products, combined with an upcoming norovirus vaccine, diversify revenue sources and reduce dependency on COVID‑19 demand.
  • The oncology pipeline represents a high‑impact catalyst, with five late‑stage trials across melanoma, renal cell carcinoma, muscle‑invasive bladder cancer, and other solid tumors now fully enrolled. The company’s individualized cancer therapy (INT) program, in partnership with Merck, has delivered a five‑year phase‑2 data set that shows a 50% reduction in relapse or death for adjuvant melanoma, a benchmark that could translate into a blockbuster approval if phase‑3 results confirm the trend. The company’s oncology portfolio also includes a phase‑2 study of mRNA‑4259, a cancer antigen therapy, and a phase‑1/2 study of a T‑cell engager, mRNA‑2808, for multiple myeloma, expanding the therapeutic potential beyond solid tumors. The breadth of the oncology pipeline, coupled with the partnership with Merck and the ability to bring these products to market faster due to the mRNA platform, creates an upside that could significantly lift the company’s earnings profile if the data streams remain positive.
  • Rare disease programs, particularly the propionic acidemia (PA) program that is fully enrolled and the upcoming methylmalonic acidemia (MMA) study, offer a stable revenue stream that is less affected by the cyclical nature of infectious disease markets. These programs target small patient populations but carry high pricing potential and strong unmet medical need, which can translate into substantial profitability once approved. The company’s ability to leverage its mRNA platform to address metabolic disorders provides a distinct competitive advantage in a niche that is underserved by traditional small‑molecule and biologic therapies. This dual focus on rare disease and oncology provides a balanced portfolio that can offset revenue volatility associated with the COVID and respiratory vaccine markets.
Read more

Bear case

  • The U.S. FDA’s refusal to file the mRNA‑1010 flu vaccine and the resulting uncertainty in the Type A meeting present a significant regulatory risk that could delay or even eliminate the company’s U.S. flu product launch. Without a U.S. presence, Moderna loses access to a market that, while smaller than the U.K. and Canada, still represents a multi‑billion‑dollar opportunity, especially for high‑risk populations. The company’s financial guidance for 2026 explicitly assumes no revenue from the flu or flu‑COVID combination in the United States, which underestimates the potential revenue loss if the U.S. market remains inaccessible. This regulatory setback also raises questions about the company’s ability to secure approvals for other respiratory products, such as the flu‑COVID combo, further dampening growth prospects.
  • Moderna’s heavy R&D spend—approximately $3 billion in 2026—combined with a net loss of $2.8 billion in 2025, highlights a sustainability concern. Even with a $5.5‑$6 billion cash balance at the end of 2026, the company’s burn rate is such that it could exhaust its runway if revenue growth stalls or if additional capital raises dilute shareholders. The company’s guidance assumes a $5.5‑$6 billion cash balance after 2026, but it does not account for potential cost overruns, unexpected regulatory delays, or lower-than‑expected product uptake, all of which could accelerate cash depletion. Investors may view this as a significant risk factor, especially in a capital‑intensive industry where market share can be lost quickly to competitors.
  • The COVID‑19 vaccine market, once a windfall source, is now a declining segment with shrinking demand. Moderna’s revenue share from COVID vaccines fell from 62% to 48% in 2026, a trend that may continue as competitors gain scale and market share, and as payers push for lower pricing. The company’s reliance on the MNEXT Spike launch to drive second‑year growth is a high‑stakes bet, and any slowdown in senior vaccination rates—due to public sentiment or regulatory changes—could severely impact revenue forecasts. The company’s financial guidance already reflects a “future potential decline” in COVID vaccination rates, indicating an awareness that this segment will not rebound to pandemic levels.
  • Competitive pressures in both the respiratory and oncology spaces could erode Moderna’s market position. Several other mRNA and traditional vaccine manufacturers are advancing similar products, and some—like Pfizer and Johnson & Johnson—have deep commercial pipelines and broader manufacturing networks. In oncology, the field is highly crowded, and the success of the INT program depends on event‑driven data that may not meet regulatory expectations. A failure in the phase‑3 melanoma data or a lack of clinical benefit in renal cell carcinoma or bladder cancer would diminish the attractiveness of the entire oncology portfolio and reduce future revenue streams.
  • Pricing and reimbursement uncertainties loom large, especially in the United States. Recent policy shifts, such as the cancellation of the $600 million government contract for high‑risk mRNA vaccine development, reflect a broader skepticism toward mRNA technology that could translate into payer hesitancy. If payers view the company’s new respiratory products as too expensive relative to existing alternatives, the company may have to offer discounts that erode margins. This risk is amplified by the fact that many new products—especially in rare disease—are priced at a premium, and reimbursement pathways for high‑cost therapies are still evolving.
Read more

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 VRTX Vertex Pharmaceuticals Inc / Ma 113.30 Bn 28.64 9.44 -
2 REGN Regeneron Pharmaceuticals, Inc. 78.40 Bn 17.37 5.47 1.99 Bn
3 ALNY Alnylam Pharmaceuticals, Inc. 41.41 Bn 150.53 13.15 -
4 MESO Mesoblast Ltd 21.68 Bn -169.86 1,260.73 0.12 Bn
5 RPRX Royalty Pharma plc 19.93 Bn 25.90 8.38 8.95 Bn
6 ZLAB Zai Lab Ltd 19.57 Bn -111.69 80.73 0.20 Bn
7 MRNA Moderna, Inc. 18.75 Bn -6.63 9.65 0.59 Bn
8 ROIV Roivant Sciences Ltd. 18.40 Bn -30.01 3,205.68 -